Equities analysts expect Mersana Therapeutics Inc (NASDAQ:MRSN) to announce $3.76 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from $3.00 million to $4.20 million. Mersana Therapeutics posted sales of $3.73 million in the same quarter last year, which would indicate a positive year over year growth rate of 0.8%. The firm is expected to report its next quarterly earnings results on Friday, August 10th.
On average, analysts expect that Mersana Therapeutics will report full year sales of $14.89 million for the current fiscal year, with estimates ranging from $12.06 million to $16.90 million. For the next year, analysts anticipate that the firm will report sales of $21.22 million per share, with estimates ranging from $14.42 million to $27.08 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings results on Monday, May 14th. The company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.07. Mersana Therapeutics had a negative net margin of 263.80% and a negative return on equity of 124.32%. The firm had revenue of $3.06 million for the quarter, compared to analyst estimates of $3.49 million.
Several equities research analysts recently commented on MRSN shares. HC Wainwright set a $33.00 price target on shares of Mersana Therapeutics and gave the stock a “buy” rating in a research note on Friday, March 2nd. JPMorgan Chase & Co. lowered shares of Mersana Therapeutics from an “overweight” rating to a “neutral” rating and set a $23.00 price target on the stock. in a research note on Monday, March 19th. Zacks Investment Research upgraded shares of Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Thursday, March 22nd. Leerink Swann reiterated an “outperform” rating on shares of Mersana Therapeutics in a research note on Wednesday, March 28th. Finally, Cowen reiterated a “buy” rating on shares of Mersana Therapeutics in a research note on Monday, April 16th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $25.33.
A number of institutional investors have recently modified their holdings of the business. ArrowMark Colorado Holdings LLC grew its position in Mersana Therapeutics by 88.4% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 899,773 shares of the company’s stock worth $14,783,000 after purchasing an additional 422,062 shares during the last quarter. BlackRock Inc. grew its position in Mersana Therapeutics by 41.7% during the 1st quarter. BlackRock Inc. now owns 818,004 shares of the company’s stock worth $12,899,000 after purchasing an additional 240,705 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Mersana Therapeutics during the 1st quarter worth $2,681,000. Northern Trust Corp grew its position in Mersana Therapeutics by 111.0% during the 1st quarter. Northern Trust Corp now owns 111,669 shares of the company’s stock worth $1,761,000 after purchasing an additional 58,743 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Mersana Therapeutics by 10.1% during the 4th quarter. Geode Capital Management LLC now owns 63,173 shares of the company’s stock worth $1,037,000 after purchasing an additional 5,821 shares during the last quarter. 81.68% of the stock is currently owned by institutional investors.
NASDAQ:MRSN traded up $0.56 during midday trading on Friday, hitting $19.21. 345,600 shares of the company were exchanged, compared to its average volume of 125,975. Mersana Therapeutics has a fifty-two week low of $12.45 and a fifty-two week high of $23.96. The firm has a market capitalization of $433.30 million and a P/E ratio of -5.77.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.